Impact on Performance from Changes in Pharmaceutical Laws, Regulations, Licenses and Permits
First written in FY2016. 14 of 16 entries say "Restated". Latest entry: FY2022.
The whole theme swung hardest in 2021: 2 of 14 companies on the "Worse" side.
16 other companies' latest entry also says "Restated".
- FY2022RestatedAnnual report
「Accordingly, depending on the status of approvals and licenses from the relevant supervisory authorities and other bodies, the performance of the wholesale business for prescription pharmaceuticals and other products may be affected. In addition, if deregulation or other developments in the future allow companies from other industries to enter the business areas of our group, it may become difficult to maintain or expand our group's business model and longstanding strengths, which could affect our group's performance and financial condition.」
The company continues to disclose the risks associated with the status of approvals and licenses and with companies from other industries entering the market as a result of deregulation. - FY2021RestatedAnnual report
「Accordingly, depending on the status of approvals and licenses from the relevant supervisory authorities and other bodies, the performance of the wholesale business for prescription pharmaceuticals and other products may be affected. In addition, if deregulation or other developments in the future allow companies from other industries to enter the business areas of our group, it may become difficult to maintain or expand our group's business model and longstanding strengths, which could affect our group's performance and financial condition.」
The company continues to disclose the risks associated with changes in approvals and licenses and with companies from other industries entering the market as a result of deregulation. - FY2021-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of the impact on performance from changes in pharmaceutical regulations, approvals and licenses. - FY2020WorsenedAnnual report
「In addition, if deregulation or other developments in the future allow companies from other industries to enter the business areas of our group, it may become difficult to maintain or expand our group's business model and longstanding strengths, which could affect our group's performance and financial condition.」
In addition to existing approvals, licenses and decisions by supervisory authorities, the company explicitly identified as a risk the potential impact on its business model of companies from other industries entering the market as a result of future deregulation. - FY2020-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of the impact on performance from changes in pharmaceutical regulations, approvals and licenses. It also states that no new risks have arisen overall. - FY2020-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of the impact on performance from changes in pharmaceutical regulations, approvals and licenses. - FY2019-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of the impact on performance from changes in pharmaceutical regulations, approvals and licenses. - FY2019-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of the impact on performance from changes in pharmaceutical regulations, approvals and licenses. - FY2019-Q1RestatedAnnual report
「No new business or other risks arose during the first quarter of the current consolidated cumulative period. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of changes in pharmaceutical regulations, approvals and licenses. - FY2018RestatedAnnual report
「Depending on the status of approvals and licenses from the relevant supervisory authorities and other bodies, the performance of the wholesale business for prescription pharmaceuticals and other products may be affected.」
The company continues to disclose as a risk the possibility that changes in pharmaceutical regulations, approvals and licenses may affect its performance. - FY2018-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of changes in pharmaceutical regulations, approvals and licenses. - FY2018-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of changes in pharmaceutical regulations, approvals and licenses. - FY2017-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter under review. In addition, there have been no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of changes in pharmaceutical regulations, approvals and licenses. - FY2017-Q2RestatedAnnual report
「During the first six months of the current consolidated fiscal year, there were no newly arising business or other risks. In addition, there were no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of changes in pharmaceutical regulations, approvals and licenses. - FY2017-Q1RestatedAnnual report
「No new business or other risks arose during the first quarter of the current consolidated cumulative period. There were also no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no material changes regarding the risk of changes in pharmaceutical regulations, approvals and licenses. - FY2016First statedAnnual report
「Primarily under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices, each business location conducts sales activities after obtaining the necessary permits, registrations, designations and licenses from the relevant prefectural governor, or after filing notifications with the relevant supervisory authorities. Depending on the status of approvals and licenses from the relevant supervisory authorities and other bodies, the performance of the wholesale business for prescription pharmaceuticals and other products may be affected.」
The company discloses as a risk the possibility that pharmaceutical-related approvals and licenses or decisions by supervisory authorities may affect its wholesale business for prescription pharmaceuticals and other products.